IAP-targeted therapies for cancer
Top Cited Papers
- 20 October 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 27 (48), 6252-6275
- https://doi.org/10.1038/onc.2008.302
Abstract
DNA damage, chromosomal abnormalities, oncogene activation, viral infection, substrate detachment and hypoxia can all trigger apoptosis in normal cells. However, cancer cells acquire mutations that allow them to survive these threats that are part and parcel of the transformation process or that may affect the growth and dissemination of the tumor. Eventually, cancer cells accumulate further mutations that make them resistant to apoptosis mediated by standard cytotoxic chemotherapy or radiotherapy. The inhibitor of apoptosis (IAP) family members, defined by the presence of a baculovirus IAP repeat (BIR) protein domain, are key regulators of cytokinesis, apoptosis and signal transduction. Specific IAPs regulate either cell division, caspase activity or survival pathways mediated through binding to their BIR domains, and/or through their ubiquitin-ligase RING domain activity. These protein-protein interactions and post-translational modifications are the subject of intense investigations that shed light on how these proteins contribute to oncogenesis and resistance to therapy. In the past several years, we have seen multiple approaches of IAP antagonism enter the clinic, and the rewards of such strategies are about to reap benefit. Significantly, small molecule pan-IAP antagonists that mimic an endogenous inhibitor of the IAPs, called Smac, have demonstrated an unexpected ability to sensitize cancer cells to tumor necrosis factor-alpha and to promote autocrine or paracrine production of this cytokine by the tumor cell and possibly, other cells too. This review will focus on these and other developmental therapeutics that target the IAPs in cancer.Keywords
This publication has 100 references indexed in Scilit:
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- XIAP Induces NF-κB Activation via the BIR1/TAB1 Interaction and BIR1 DimerizationMolecular Cell, 2007
- Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinicCancer Treatment Reviews, 2007
- Ubiquitination of RIP1 Regulates an NF-κB-Independent Cell-Death Switch in TNF SignalingCurrent Biology, 2007
- Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinomaCancer, 2007
- Splice variants of mIAP1 have an enhanced ability to inhibit apoptosisBiochemical and Biophysical Research Communications, 2006
- Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic ApproachCell, 2006
- Activation of IKK by TNFα Requires Site-Specific Ubiquitination of RIP1 and Polyubiquitin Binding by NEMOMolecular Cell, 2006